GSK Says Herpes Vaccine Candidate Study Failed to Meet Primary Objective
By Anthony O. Goriainoff
GSK said the phase 2 trial of its herpes vaccine candidate didn't meet its primary efficacy objective and therefore won't progress to a phase 3 study.
The U.K. biopharma company said Wednesday that no safety concerns were seen during the study of GSK3943104, its early-stage therapeutic herpes simplex virus, or HSV, vaccine candidate.
The company said it will continue with its HSV research for routine safety monitoring and create follow-up data that could offer insights into genital herpes.
"GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV program," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 11, 2024 02:38 ET (06:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
United States